Table 1

Clinical and demographic characteristics of the study population

Variable

PsA subjects (number = 270)

Male gender

124 (45.9%)

Age (years)

51.73 ± 11.49

Disease subset

Axial + peripheral

95 (35.2%)

Peripheral

95 (35.2%)

Axial

64 (23.7%)

Mutilans

16 (5.9%)

MetS

91 (33.7%)

HS

76 (28.1%)

CPs

58 (21.5%)

Concomitant MTX

111 (41.1%)

Disease duration (years)

4.87 ± 2.94

ESR (mm/h)

18.05 ± 13.19

CRP (mg/L)

2.64 ± 2.93

SJC

3.77 ± 4.08

TJC

11.93 ± 5.48

PASI

1.48 ± 0.71

HAQ

2.47 ± 1.45

VAS

76.7 ± 20.12

Patient global VAS

74.25 ± 22.38

Tender entheseal count

10.97 ± 5.40

Hypercholesterolemia

139 (51.5%)

Hypertriglyceridemia

92 (34.1%)

Impaired fasting glucose

20 (7.4%)

Hypertension

57 (21.1%)

Smoking habit

65 (24.1%)

Obesity

111 (41.1%)

CPs, presence of carotid plaques (carotid intima-media thickness > 1.3 mm); CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; HS, hepatic steatosis; MetS, metabolic syndrome; MTX: Methotrexate; PASI, Psoriasis Area Severity Index; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analogue Scale for pain.

Di Minno et al. Arthritis Research & Therapy 2012 14:R211   doi:10.1186/ar4049